duloxetine (cas 116539-58-3) plasma level and antidepressant response

Add time:08/15/2019    Source:sciencedirect.com

BackgroundMajor Depressive Disorder (MDD) is associated with a high rate of inadequate treatment response, which is mainly due to the large inter-individual genetic variability in pharmacokinetic and pharmacodynamic targets of antidepressant drugs. Little is still known about the exact association between plasma level of first-line antidepressants and clinical response. This is particularly true for duloxetine (cas 116539-58-3), a dual serotonin and norepinephrine reuptake inhibitor recommended as first-line treatment for MDD. The aim of this study was to investigate the association between serum concentration of duloxetine (SCD) and antidepressant response (AR).

We also recommend Trading Suppliers and Manufacturers of duloxetine (cas 116539-58-3). Pls Click Website Link as below: cas 116539-58-3 suppliers

Prev:Stability and toxicity studies for duloxetine (cas 116539-58-3) and econazole on Spirodela polyrhiza using chiral capillary electrophoresis
Next:Preclinical evidence of enhanced analgesic activity of duloxetine (cas 116539-58-3) complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes)